The Ki-67 index in non-Hodgkin's Lymphoma: Role and Prognostic Significance

Mehrdad Payandeh¹, Masoud Sadeghi^{2, 3,} and Edris Sadeghi^{2, 3}

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi and Edris Sadeghi. The Ki-67 index in non-Hodgkin's Lymphoma: Role and Prognostic Significance. American Journal of Cancer Prevention. 2015; 3(5):100-102. doi: 10.12691/ajcp-3-5-7

Abstract

Background: Ki67 is a nuclear and nuclear protein antigen present in all proliferating cells during the active part of the cell cycle: G1, S, G2, and mitosis. The aim of study is to evaluate survival based on Ki67 index in NHL patients in the west of Iran for the first time. Patients and Methods: Between of 2002 to 2014, fifty-six patients with NHL referred to Our Clinic. We checked age, sex, type of NHL, Ki67 index and survival for them. We divided Ki67 index to two groups: low Ki67 (Ki67<65%) and high Ki67 (Ki67≥65%). Results: The mean age at diagnosis for patients was 47.33±166.50 years (range, 13-77 years) that 27 patients (48.2%) had age≤ 50 years and 33 patients (58.9%) were male. Thirty-eight patients (67.9%) had Ki67<60% and 18 patients (32.1%) had Ki67≥65%. The mean Ki67 for Nodal patients was 48.1% and for extra nodal was 54.5%, but there was no significant correlation between them (P=0.360). Conclusion: Ki67 in future studies should be divided based on a fix percent until we can have a better result about the role of Ki67 in NHL patients. Also, Ki67 alone can not be a risk factor in NHL patients and other factors such as age, sex and type of NHL can be affective, too.

Keywords:
Ki67 index overall survival NHL

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, et al, Mujtuba S, Malik B. Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev. 2013. 14 (7): 4353-8.
[2]	Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various genesignatures in breast cancer. Cancer Sci. 2012. 103 (8): 1508-12.
[3]	Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002. 40 (1): 2-11.
[4]	Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000. 257 (2): 231-7.
[5]	Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006. 24 (16): 2472-9. Epub 2006 Apr 24.
[6]	Hadzi-Pecova L, Petrusevska G, Stojanovic A. Non-Hodgkin's lymphomas: immunologic prognostic studies. Prilozi. 2007. 28 (1): 39-55.
[7]	Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011; 126 (1): 44-51.
[8]	Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009. 84 (6): 338-43.
[9]	Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007. 18 (8): 1382-7.
[10]	Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, et al Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol. 2004. 83 (7): 414-9. Epub 2004 Apr 14.
[11]	Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 1988. 154 (3): 223-35.
[12]	Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006. 24 (16): 2472-9. Epub 2006 Apr 24.
[13]	Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994. 83 (6): 1460-6.
[14]	Gribben J, Steward A, Casce L. Clinical manifestations, staging, and treatment of non-Hodgkin lymphoma. In: Hoffman R, Benz E, Shattil S, et al., editors. Hematology: Basic Principles & Practice. Philadelphia: Elsevier; 2005. pp 1397-1419.